Form 4: Ingevity Director J. Kevin Willis Increases Stake Through Deferred Stock Units

Ingevity Corp Director J. Kevin Willis acquired 620 shares of common stock on July 1, 2025, through the vesting of deferred stock units received in lieu of director fees.

Summary

• J. Kevin Willis, a Director of Ingevity Corp (NGVT), acquired 620 shares of common stock.
• The transaction occurred on July 1, 2025.
• These shares represent vested deferred stock units (DSUs) granted pursuant to Mr. Willis's election to receive DSUs in lieu of quarterly director fees.
• The DSUs will settle into an equal number of shares of the Company's Common Stock upon Mr. Willis's termination of board service, as per the Company's Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
• The acquisition price was $44.4 per share.
• Following this transaction, J. Kevin Willis directly beneficially owns 7,794 shares of Ingevity Corp common stock.

Sentiment

Score: 7

Explanation: The transaction is a positive signal of insider confidence and aligns director interests with shareholders, though it is a routine compensation event rather than a discretionary open-market purchase.

Positives

• Director J. Kevin Willis increased his direct beneficial ownership in Ingevity Corp by 620 shares, indicating continued alignment with shareholder interests.
• The acquisition was through the vesting of deferred stock units, a common practice for non-employee directors to defer compensation and increase equity ownership, aligning their long-term interests with the company's performance.

Future Outlook

The acquired deferred stock units will settle into physical common stock upon J. Kevin Willis's termination of board service, aligning his future compensation with the company's long-term performance.

Industry Context

Insider transactions, particularly acquisitions by directors through compensation plans, are generally viewed as a positive signal of confidence in the company's future prospects. This transaction reflects a standard practice of non-employee director compensation through equity, common across various industries to align director incentives with shareholder value.

Comparison to Industry Standards

• The practice of compensating non-employee directors with deferred stock units in lieu of cash fees is a common corporate governance practice across various industries, including specialty chemicals, aligning director interests with long-term shareholder value.
• The specific value of $44.4 per share for the acquisition aligns with the market price of Ingevity Corp's common stock around the transaction date, which is standard for DSU conversions and reflects the fair market value at the time of vesting.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership, potentially fostering more long-term strategic decisions.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The acquired deferred stock units will convert into physical shares of Ingevity Corp common stock upon J. Kevin Willis's termination of board service, as per the company's compensation plans.

Key Dates

Recommendation

Keywords

Ingevity Corp, NGVT, Form 4, Insider Transaction, Director Compensation, Deferred Stock Units, Equity Ownership, J. Kevin Willis